D-galactopyranosyl-α-(1->2)-D-chiro-inositol | 79391-04-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-galactopyranosyl-α-(1->2)-D-chiro-inositol
• 英文别名: O-α-D-galactopyranosyl-(1->2)-D-chiroinositol；fagopyritol B1；2-O-α-D-galactopyranosyl-D-chiro-inositol；1D-2-O-(α-D-galactopyranosyl)-chiro-inositol
• CAS: 79391-04-1
• 化学式: C₁₂H₂₂O₁₁
• 分子量: 342.3
• InChiKey: VCWMRQDBPZKXKG-ADKCXELFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.01
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  200.53
• 氢给体数：
  9.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  D-galactopyranosyl-α-(1->2)-D-chiro-inositol 生成 1D-4-O-acetyl-1,2,3,5,6-penta-O-methyl-myo-inositol
  参考文献：
  名称：

  Purification and structure determination of three α-d- galactopyranosylcyclitols from soya bean

  摘要：

  DOI：

  10.1016/s0008-6215(00)85295-7
• 作为产物：
  描述：

  3,4,5,6-tetra-O-benzyl-D-chiro-inositol 在 钯 三氟甲磺酸三甲基硅酯 、 四丁基溴化铵 、 氢气 、 sodium hydride 、 二正丁基氧化锡 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 paraffin 为溶剂， -78.0~25.0 ℃ 、275.79 kPa 条件下， 反应 44.42h， 生成 D-galactopyranosyl-α-(1->2)-D-chiro-inositol
  参考文献：
  名称：

  Synthesis of a jojoba bean disaccharide

  摘要：

  A synthesis of the disaccharide recently isolated from jojoba beans, 2-O-alpha-D-galactopyranosyl-D-chiro-inositol, has been achieved. The suitably protected chiro-inositol unit was prepared by an enantiospecific synthesis from L-xylose utilizing SmI2-mediated pinacol coupling as a key step. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0008-6215(98)00168-2

文献信息

• Controlled release alpha lipoic acid formulation with an inositol compound
  申请人：Byrd A. Edward

  公开号：US20060024367A1

  公开（公告）日：2006-02-02

  A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.

  本发明公开了一种用于口服的肌醇化合物和硫辛酸的双相制剂。将硫辛酸和肌醇化合物与赋形剂材料结合在一起，使这些材料能够立即从制剂中释放出第一部分活性成分，然后逐渐释放剩余的活性成分，从而能够：(1) 快速获得活性成分的治疗水平；(2) 与快速释放制剂相比，大大延长维持活性成分治疗水平的时间。这些特点使得使用该制剂降低血清葡萄糖水平并长期维持降低的葡萄糖水平以治疗糖尿病多发性神经病变成为可能，从而获得一系列预期的治疗效果。
• Synthesis of fagopyritols A1 and B1 from d-chiro-inositol
  作者：M. Belén Cid、Francisco Alfonso、Manuel Martín-Lomas

  DOI：10.1016/j.carres.2004.06.021

  日期：2004.9

  Fagopyritol Al (3-O-alpha-D-galactopyranosyl-D-chiro-inositol) and fagopyritol B1 (2-O-alpha-D-galactopyranosyl-D-chiro-inositol) have been synthesized by glycosylation of the diequatorial diol 1,4,5,6-tetra-O-benzoyl-D-chiro-inositol, readily obtained from D-chiro-inositol, with 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl trichloroacetimidate. (C) 2004 Elsevier Ltd. All rights reserved.